Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record.

Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy

Open access
Cometta, A., Kern, W. V., De Bock, R., Paesmans, M., Vandenbergh, M., Crokaert, F., Engelhard, D., Marchetti, O., Akan, H., Skoutelis, A., Korten, V., Vandercam, M., Gaya, H., Padmos, A., Klastersky, J., Zinner, S., Glauser, M. P., Calandra, T., Viscoli, C., The International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer·2003·Clinical Infectious Diseases

Abstract

This prospective, double-blind trial assessed whether the addition of a glycopeptide would be able to reduce the time to defervescence in neutropenic patients with cancer who had persistent fever 48-60 h after the initiation of empirical piperacillin-tazobactam monotherapy. Of 763 eligible patients, 165 with persistent fever were randomized to receive piperacillin-tazobactam therapy plus either vancomycin therapy or placebo. Defervescence was observed in 82 (95%) of 86 patients in the vancomycin group and in 73 (92%) of 79 patients in the placebo group (P=.52). The distributions of the time to defervescence were not statistically significant between the 2 groups (estimated hazard ratio, 1.03; 95% confidence interval, 0.75-1.43; P=.75). The number of additional episodes of gram-positive bacteremia and the percentage of patients for whom amphotericin B was empirically added to their therapy regimen were also similar in both groups. This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/376637

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Cometta, A., Kern, W. V., De Bock, R., Paesmans, M., Vandenbergh, M., Crokaert, F., Engelhard, D., Marchetti, O., Akan, H., Skoutelis, A., Korten, V., Vandercam, M., Gaya, H., Padmos, A., Klastersky, J., Zinner, S., Glauser, M. P., Calandra, T., Viscoli, C., & The International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer
Venue
Clinical Infectious Diseases
Published
2003-08-01
Volume
37
Issue
3
Pages
382-389
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2104013660
Cited by
168
References
0
FWCI
5.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy. https://app.cochat.ai/papers/10.1086/376637
The paper
Cometta, A., Kern, W. V., De Bock, R., Paesmans, M., Vandenbergh, M., Crokaert, F., Engelhard, D., Marchetti, O., Akan, H., Skoutelis, A., Korten, V., Vandercam, M., Gaya, H., Padmos, A., Klastersky, J., Zinner, S., Glauser, M. P., Calandra, T., Viscoli, C., & The International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer. (2003). Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy. Clinical Infectious Diseases. https://doi.org/10.1086/376637

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.